laquinimod: Clinical Trials

6 trials of laquinimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated. 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 26Completed 5, Terminated 1

Follow laquinimod: new trials by email Literature Review of laquinimod trials Research Report on laquinimod

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Placebo, Laquinimod - Primary Progressive Multiple Sclerosis
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.3742015-01-122022-03-10
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
Laquinimod, Placebo - Huntington's Disease
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.3522014-10-282020-05-04
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
Laquinimod, Placebo - Lupus Arthritis
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.822010-10-042022-07-07
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone - Lupus Nephritis
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.462010-09-012022-03-09
Laquinimod Phase IIa Study in Active Crohn's Disease
Laquinimod, placebo - Crohn's Disease
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.1802010-05-012015-03-20
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
Laquinimod, Placebo - Relapsing Remitting Multiple Sclerosis
Phase 2TerminatedTeva Pharmaceutical Industries, Ltd.2572005-12-072019-03-27

Conditions studied

Lupus Erythematosus, Systemic (2)  ·  Crohn Disease (1)  ·  Huntington Disease (1)  ·  Lupus Nephritis (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Chronic Progressive (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc. (5)  ·  Teva Pharmaceutical Industries, Ltd. (1)

Countries

United Kingdom (5)  ·  Canada (4)  ·  Italy (4)  ·  Russia (4)  ·  Spain (4)  ·  United States (4)  ·  Germany (3)  ·  Netherlands (3)  ·  Poland (3)  ·  Czechia (2)  ·  France (2)  ·  Israel (2)  ·  Belgium (1)  ·  Hungary (1)  ·  Portugal (1)

Top investigators

Geert D'Haens, MD PhD (1)  ·  Giancarlo Comi (1)

Results publications

PMID 25281416, PMID 27296315, PMID 32651286, PMID 36163349, PMID 38280392

NIH funding

2014 (2), 2005 (1)